South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

Sydney, Jan 10, 2026, 17:28 AEDT — Market closed

South32 Ltd shares rose 1.1% to close at A$3.85 on Friday, sitting just under their 2026 high of A$3.87 as investors lined up the next catalysts for the miner. (Intelligent Investor)

South32 on Friday published its 2026 calendar of key dates, putting its half-year results on Feb. 12 and setting the timetable for an interim dividend across its ASX, London and Johannesburg listings. The miner said the ASX and LSE ex-dividend date — the first day the stock trades without the right to the payout — is March 5, with payment due on or around April 2, subject to board approval.

That matters now because South32’s dividend call is often treated as a shorthand for cash flow and balance-sheet headroom, and the February report is the first major company update of the year. Traders will be looking for cost trends and any changes in production and spending signals.

The wider market was subdued on Friday. The S&P/ASX 200 slipped 0.03% and the metals & mining sector was among the laggards, while Rio Tinto fell 6.2% in Sydney trade. (Investing)

Mining valuations have also been knocked around by renewed merger chatter. Glencore shares jumped more than 10% after it confirmed early talks with Rio Tinto about a takeover that would create a group valued at almost $207 billion, Reuters reported, as copper prices hit record levels this week. “The record is dreadful for the big majors making acquisitions or even mergers,” said Hugh Dive, chief investment officer of Atlas Funds Management. (Reuters)

But South32 carries its own near-term uncertainty. The company said in December it would put the Mozal aluminium smelter in Mozambique under “care and maintenance” — a temporary shutdown — by March after failing to secure a power deal, and flagged a $60 million one-off cost. (Reuters)

With the market shut until Monday, attention shifts back to commodities and whether the stock can push through the A$3.87 peak without a stumble on costs or guidance.

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Wesfarmers stock (ASX:WES) ends at A$81 — the next dates investors are circling
Previous Story

Wesfarmers stock (ASX:WES) ends at A$81 — the next dates investors are circling

BlueScope Steel (ASX:BSL) stock pinned at A$30 after AustralianSuper backs takeover snub
Next Story

BlueScope Steel (ASX:BSL) stock pinned at A$30 after AustralianSuper backs takeover snub

Go toTop